Börskollen
Pressmeddelanden från FluoGuide
25 feb 07:09
FluoGuideFluoGuide A/S publishes annual report for the fiscal year 202525 feb 07:07FluoGuideFluoGuide A/S publishes interim report for Q4 202520 feb 20:40FluoGuideFDA clears FluoGuide’s IND for FG001 in High-Grade Glioma; U.S. clinical trial remains on track19 feb 09:16FluoGuideInvitation to FluoGuide A/S (Nasdaq: FLUO) live webcast on 25 February 202621 jan 08:21FluoGuideFluoGuide submits an IND for FG001, to initiate first U.S. registration trial19 dec 2025 11:57FluoGuideFluoGuide updates IND submission timing for FG001 – trial initiation unaffected27 nov 2025 07:18FluoGuideFluoGuide A/S publishes Interim Report Q3 202525 nov 2025 14:59FluoGuideFluoGuide signs collaboration agreement with ZEISS24 nov 2025 16:14FluoGuideMinutes from Extraordinary General Meeting in FluoGuide A/S24 nov 2025 11:05FluoGuideInvitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 27 November 202505 nov 2025 17:27FluoGuideFluoGuide strengthens leadership to advance clinical program and regulatory approval strategy05 nov 2025 17:22FluoGuideFluoGuide convenes an extraordinary general meeting03 nov 2025 21:54FluoGuideFluoGuide A/S issue warrants to board members, executive management and employees03 nov 2025 21:30FluoGuideShare transfer and ownership restructuring – related party transaction03 nov 2025 21:28FluoGuideFluoGuide A/S completes directed share issue of SEK 104 million03 nov 2025 17:43FluoGuideFluoGuide A/S intends to carry out a directed share issue of approximately SEK 100 million28 okt 2025 13:47FluoGuideFluoGuide in advanced negotiations on collaboration agreement with a world leading medical technology company06 okt 2025 09:05FluoGuidePositive interim results from an investigator-initiated study of FG001 in meningioma and low-grade glioma surgery, presented at EANS16 sep 2025 11:01FluoGuideFluoGuide receives positive FDA feedback on FG001 in high-grade glioma28 aug 2025 07:28FluoGuideFluoGuide A/S publishes Interim Report H1 202522 aug 2025 12:51FluoGuideInvitation to FluoGuide A/S (Nasdaq: FLUO) webcast on 28 August 202521 jul 2025 13:46FluoGuideFluoGuide enters collaboration with global MedTech company Olympus03 jul 2025 14:56FluoGuideUpdate on 2025 Outlook and Company progress10 jun 2025 09:02FluoGuideFG001 clinical data in High-Grade Glioma is now published in Neurosurgery28 maj 2025 07:06FluoGuideFluoGuide A/S publishes interim report for the period January – March 2025 - On track - first patients enrolled in CT-00515 apr 2025 10:28FluoGuideFluoGuide includes first patient in phase II trial of FG001 for head and neck cancer27 mar 2025 15:50FluoGuideMinutes from Annual General Meeting in FluoGuide A/S12 mar 2025 09:49FluoGuideNotice of Annual General Meeting in FluoGuide A/S27 feb 2025 07:03FluoGuideFluoGuide A/S publishes year-end and annual report for the fiscal year 202427 feb 2025 07:00FluoGuideFluoGuide A/S publishes interim report for the period January – December 202415 jan 2025 16:34FluoGuideFluoGuide A/S receives approval for phase II trial in head and neck cancer27 nov 2024 07:00FluoGuideFluoGuide A/S publishes interim report for the period January – September 202419 nov 2024 13:43FluoGuidePublication of positive phase II clinical data for FG001 in patients with head and neck cancer12 nov 2024 18:23FluoGuideFluoGuide A/S issue warrants to board member, CMO and CFO21 okt 2024 16:13FluoGuideRoger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide07 okt 2024 13:13FluoGuideFluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer29 aug 2024 08:55FluoGuideFluoGuide A/S publishes interim report for the period January – June 202426 aug 2024 09:05FluoGuideFluoGuide appoints Jens Ellrich as Chief Medical Officer18 jun 2024 23:12FluoGuideFluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million18 jun 2024 17:31FluoGuideFluoGuide intends to carry out a directed share issue of approximately SEK 60 million30 maj 2024 08:51FluoGuideFluoGuide A/S publishes interim report for the period January – March 202427 maj 2024 09:40FluoGuideFluoGuide selects laser system for photothermal cancer therapy with FG00120 mar 2024 14:25FluoGuideMinutes from Annual General Meeting in FluoGuide A/S13 mar 2024 11:17FluoGuideChief Financial Officer (CFO) Ole Larsen buys shares12 mar 2024 12:12FluoGuideFluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company01 mar 2024 12:41FluoGuideNotice of Annual General Meeting in FluoGuide A/S28 feb 2024 08:10FluoGuideFluoGuide A/S publishes year-end and annual report for the fiscal year 202323 feb 2024 16:02FluoGuideFluoGuide A/S issues warrants to CFO08 jan 2024 11:33FluoGuideFluoGuide provides strategic update and outlines development plans towards commercialization of FG00109 dec 2023 16:17FluoGuideChief Development Officer (CDO) Grethe Nørskov Rasmussen sells shares08 dec 2023 09:55FluoGuideFluoGuide raises SEK 12 million through exercise of warrants29 nov 2023 08:00FluoGuideFluoGuide A/S publishes interim report for the period January – September 202313 nov 2023 08:35FluoGuideFluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer06 nov 2023 10:01FluoGuideFluoGuide confirms positive topline results from phase lla trial of FG001 in head & neck cancer at International Academy of Oral Oncology conference03 okt 2023 10:34FluoGuideFluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma08 sep 2023 12:00FluoGuideFluoGuide receives Danish award for the best share price performance since IPO07 sep 2023 14:32FluoGuidePositive interim data from phase lla trial of FG001 in head & neck cancer presented as a case report at the World Molecular Imaging Congress in Prague30 aug 2023 08:05FluoGuideFluoGuide A/S publishes interim report for the period January – June 202329 aug 2023 09:32FluoGuideFluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer28 aug 2023 16:15FluoGuideFluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer28 aug 2023 12:53FluoGuideFluoGuide A/S issues warrants to the investors participating in the directed share issue31 jul 2023 18:42FluoGuideFluoGuide A/S issues warrants to Board members, management and employees25 jul 2023 16:12FluoGuideMinutes from Extraordinary General Meeting in FluoGuide A/S07 jul 2023 13:35FluoGuideFluoGuide convenes an extraordinary general meeting05 jul 2023 13:33FluoGuideFluoGuide completes a Directed Share Issue raising SEK 15 million20 jun 2023 08:18FluoGuideFluoGuide announces positive interim results from phase IIa trial of FG001 in head & neck cancer07 jun 2023 09:00FluoGuideFluoGuide announces positive topline results from phase IIa trial of FG001 in lung cancer31 maj 2023 08:20FluoGuideFluoGuide A/S publishes interim report for the period January – March 202324 maj 2023 09:52FluoGuideFluoGuide provides update on strong clinical trial progress21 mar 2023 12:04FluoGuideFluoGuide awarded prestigious grant together with two academic partners21 mar 2023 11:47FluoGuideMinutes from Annual General Meeting in FluoGuide A/S06 mar 2023 22:27FluoGuideNotice of Annual General Meeting in FluoGuide A/S28 feb 2023 09:00FluoGuideFluoGuide A/S publishes Year-end and annual report for the fiscal year 202227 feb 2023 09:25FluoGuideFluoGuide updates on recruitment in phase IIb aggressive brain cancer trial with FG00102 feb 2023 08:40FluoGuideFluoGuide appoints Ole Larsen as CFO25 jan 2023 13:50FluoGuideCFO acquired shares in FluoGuide09 jan 2023 10:30FluoGuideFluoGuide releases positive interim result of FG001 in head and neck cancer24 nov 2022 07:45FluoGuideFluoGuide A/S publishes interim report for the period January – September 202221 nov 2022 13:06FluoGuideFluoGuide has enrolled the first patient in the phase IIa trial in head and neck cancer08 nov 2022 08:33FluoGuideFluoGuide reaches milestone with FG001 for phase III clinical supply06 nov 2022 15:53FluoGuideFluoGuide releases positive interim result of FG001-CT002, a phase IIa trial evaluating FG001 in patients with non-small cell lung cancer (NSCLC) undergoing surgery20 okt 2022 12:07FluoGuideFluoGuide has enrolled the first patient in the phase IIb trial in aggressive brain cancer06 okt 2022 09:54FluoGuidePresentation of phase l/lla clinical data of FG001 in aggressive brain cancer at the European Congress of Neurosurgery 202203 okt 2022 13:01FluoGuideThe excellent phase I/IIa clinical data of FG001 in aggressive brain cancer was presented at the World Molecular Imaging Congress06 sep 2022 13:46FluoGuideFluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer31 aug 2022 15:01FluoGuideFluoGuide appoints new CFO30 aug 2022 09:28FluoGuideFluoGuide receives permission to start phase IIb trial in aggressive brain cancer25 aug 2022 09:23FluoGuideFluoGuide A/S publishes interim report for the period January – June 202224 aug 2022 12:23FluoGuideFluoGuide’s update on FG001’s clinical development23 aug 2022 08:18FluoGuideFluoGuide has submitted a Clinical Trial Application (CTA) to the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer22 aug 2022 15:13FluoGuidePublication of clinical data confirming uPAR as an attractive target for guiding surgery in head and neck cancer31 maj 2022 08:24FluoGuideFluoGuide A/S publishes interim report for the period January – March 202206 maj 2022 12:41FluoGuideFluoGuide invites to presentation of FG001 results from the first clinical trial in aggressive brain cancer on 17 May 202202 maj 2022 12:29FluoGuideAnnual General Meeting Copenhagen, Denmark, 2 May 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) hereby convenes an annual general meeting to be held on 18 May 2022.01 apr 2022 12:29FluoGuideFluoGuide announces positive top line result from the first part of the ongoing clinical phase I/II trial testing the safety and performance of FG001 in lightening up aggressive brain cancer30 mar 2022 08:28FluoGuideFluoGuide A/S publishes Year-end and annual report for the fiscal year 202129 mar 2022 18:56FluoGuideFluoGuide A/S issue warrants to employees and management24 mar 2022 12:24FluoGuideFluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer18 mar 2022 10:27FluoGuideFluoGuide has been awarded a grant together with Rigshospitalet (DK) to conduct a phase II trial with FG001 in patients with less aggressive brain cancers10 mar 2022 20:58FluoGuideFluoGuide has completed a directed share issue raising approximately SEK 25 million
FluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuideFluoGuide